How long was nora ephron sick

Follow Us. Terms Privacy Policy. Part of HuffPost Wellness. All rights reserved. Note: This post was updated at a. Suggest a correction. Now What? Although her movies raked in tens of millions of dollars at box offices worldwide, Ephron never won the industry's highest honor, an Academy Award. After box office flops "Hanging Up" and "Lucky Numbers" in , Ephron focused on essays, writing for the stage, and blogging for the online news site The Huffington Post. Ephron was married three times and is survived by her husband of more than 20 years, writer Nicholas Pileggi, and two children with Bernstein.

Share your memories of your favorite of her works on our Facebook page. IE 11 is not supported. For an optimal experience visit our site on another browser. Share this —. For you. World globe An icon of the world globe, indicating different international options. Get the Insider App. Click here to learn more. A leading-edge research firm focused on digital transformation. Good Subscriber Account active since Shortcuts. Decitabine , sold as Dacogen and approved in to treat MDS, is another option.

The drug's maker wants FDA approval to use Dacogen in AML patients 65 years and older and who are not considered good candidates for high-dose chemotherapy as an initial treatment for AML. However, the only curative treatment is stem cell transplantation. Stem cells are infused just like a blood transfusion. Sources of stem cells include cord blood cells, peripheral blood mobilized stem cells or bone marrow.

Success depends on the stage of disease. The one-year treatment related mortality is approximately 20 percent. If patients are transplanted in an early stage of the disease, we have a success rate of 80 percent. Are there any promising treatments in late-stage testing? We currently have a phase III trial open with a drug called rigosertib for patients who have failed prior treatment with azacitidine or decitabine, which are known as demethylating agents.

The proposed mechanism of action for these drugs is that they alter gene expression profiles in the cancer cells and increase their susceptibility to death. Rigosertib is a cell cycle inhibitor and would prevent the cancer cells from growing and induce direct damage to the cancer cells, causing their death.

Larry Greenemeier is the associate editor of technology for Scientific American , covering a variety of tech-related topics, including biotech, computers, military tech, nanotech and robots. Already a subscriber?

Sign in.